Study design and treatment
ANDROMEDA is a randomized, open-label, active-controlled, phase 3 study. Patients were randomized (1:1) to receive VCd with or without DARA SC (daratumumab 1800 mg co-formulated with recombinant human hyaluronidase PH20 [2000 U/mL; ENHANZE